Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Valenza

Physical Medicine & Rehabilitation Chester, NJ Medical Doctor

NPI 1316935372 CMS profile 150502

201 Pleasant Hill Rd, Chester, NJ 07930

Open in the dashboard

General payments

$28,863

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Valenza of Chester, NJ is reported in the CMS Open Payments database as having received $28,863 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $158 10
2024 General $191 24
2023 General $45 2
2022 General $14 1
2020 General $7,212 19
2019 General $21,242 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Valenza
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Joseph Valenza were reported at $158. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Joseph Valenza Physical Medicine & Rehabilitation median Middle half National median
2019 $21,242 $133 $45–$390 $163
2020 $7,212 $88 $29–$272 $114
2021 $0 $116 $33–$360 $132
2022 $14 $123 $40–$378 $149
2023 $45 $131 $43–$396 $160
2024 $191 $141 $45–$409 $164
2025 $158 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $16,547 27 payments
  2. AcelRx Pharmaceuticals, Inc. $6,513 10 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $3,981 10 payments
  4. Biodelivery Sciences International, Inc. $892 2 payments
  5. Collegium Pharmaceutical, Inc. $261 30 payments
  6. Avanir Pharmaceuticals, Inc. $98 7 payments
  7. AbbVie, Inc. $77 5 payments
  8. Merz North America, Inc. $71 4 payments
  9. Scilex Pharmaceuticals Inc. $46 3 payments
  10. AstraZeneca Pharmaceuticals LP $45 3 payments
  11. Other $332 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,025 5 payments
  2. Honoraria $5,880 4 payments
  3. Travel and Lodging $4,298 21 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,000 1 payment
  5. Food and Beverage $1,660 92 payments
Products named General payments · program years 2019–2025
  1. Morphabond ER $16,547 27 payments
  2. DSUVIA $6,513 10 payments
  3. RELISTOR $3,981 10 payments
  4. BELBUCA $880 1 payment
  5. XTAMPZA $261 30 payments
  6. NUEDEXTA $98 7 payments
  7. Xeomin $90 5 payments
  8. BOTOX Botox Therapeutic $77 5 payments
  9. MOVANTIK $45 3 payments
  10. BOTOX Hyperhydrosis $42 3 payments
  11. Other $386 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,714

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$572,258

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

49%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 222 $239,605
Percocet Oxycodone Hcl/Acetaminophen Brand 26 $114,510
Belbuca Buprenorphine Hcl Brand 83 $48,357
Xtampza Er Oxycodone Myristate Brand 40 $41,911
Morphine Sulfate Er Morphine Sulfate Brand 367 $25,195
Fentanyl Generic 110 $22,247
Oxycodone Hcl Generic 516 $14,713
Butrans Buprenorphine Brand 32 $11,144
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 291 $8,166
Lidocaine Generic 46 $7,984

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$102,826

Medicare's payments for the services billed

Medicare patients

90

Average age 65

Services billed

1,008

52 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 58%
Depression 49%
Diabetes 26%
Osteoporosis 23%
Ischemic heart disease 22%
Atrial fibrillation 14%
Chronic kidney disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $159
$159 40 —
HORIZANT
  • CutisPharma, Inc. $17
$17 — —
BOTOX
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record